Clinuvel Pharmaceuticals : Appendix 4C

CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; XETRA-DAX: UR9; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY), a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders announced today its Appendix 4C - Quarterly Cashflow report for the period ended 31 March 2017.

The cash balance as at 31 March 2017 was $18,772,000, a decrease of $788,000 from the end of the previous quarter.

Cash receipts for the quarter were $1,597,000 compared to $4,352,000 for the previous quarter. The expected decrease in receipts reflects the seasonal supply cycles of SCENESSE® in Europe whereby treatment for erythropoietic protopophyria is expected to increase in the spring and summer months.

Payments (net of GST refunds) for the quarter were $2,040,000, compared to $2,329,000 for the previous quarter. The combination of cash receipts and lower expenditures contributed to a net operating cash outflow result of $379,000 for the quarter ended 31 March 2017.

- End -

About SCENESSE® (afamelanotide 16mg)

SCENESSE® (afamelanotide 16mg) is approved in Europe as an orphan medicinal product for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with EPP. The innovative nature of the therapy in an orphan disorder, the lack of available scientific instruments to adequately measure the therapy, ethical considerations and the drug's positive safety profile were some of the factors which led to the European marketing authorisation of SCENESSE®. Information on the product can be found on CLINUVEL's website at www.clinuvel.com

About CLINUVEL PHARMACEUTICALS LIMITED

CLINUVEL PHARMACEUTICALS LTD (ASX: CUV; NASDAQ INTERNATIONAL DESIGNATION ADR: CLVLY; XETRA-DAX: UR9) is a global biopharmaceutical company focused on developing and delivering treatments for patients with a range of severe genetic and skin disorders. As pioneers in understanding the interaction of light and human biology, CLINUVEL's research and development has led to innovative treatments for patient populations with a clinical need for photoprotection and repigmentation. These patient groups range in size from 5,000 to 45 million worldwide. CLINUVEL's lead compound, SCENESSE® (afamelanotide 16mg), was approved by the European Commission in 2014 for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). More information on EPP can be found at http://www.epp.care.

Headquartered in Melbourne, Australia, CLINUVEL has operations in Europe, Switzerland, the US and Singapore.

For more information go to http://www.clinuvel.com.

SCENESSE® is a registered trademark of CLINUVEL PHARMACEUTICALS LTD.

Media enquiries

Investor enquiries

Forward-Looking Statements

This release to the Australian Securities Exchange and to press may contain forward-looking statements, including

statements regarding future results, performance or achievements. These statements involve known and unknown

risks, uncertainties and other factors which may cause CLINUVEL's actual results, performance or achievements to

be materially different from any future results, performances or achievements expressed or implied by the

forward-looking statements. These statements reflect our current views with respect to future events and are

based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place

undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking

statements contained herein include: that the FDA may require additional studies beyond the studies planned for

product candidates or may not provide regulatory clearances, including for SCENESSE®; that the FDA may not

provide regulatory approval for any use of SCENESSE® or that the approval may be limited; that CLINUVEL may

never file an NDA for SCENESSE® regulatory approval in the US; that the Company may not be able to access

adequate capital to advance its vitiligo programs; that the Company may not be able to retain its current

pharmaceutical and biotechnology key personnel and knowhow for further development of its product candidates

or may not reach favourable agreements with potential pricing and reimbursement agencies in Europe and the US.

Level 6, 15 Queen Street T +61 3 9660 4900 www.clinuvel.com

Melbourne, Victoria 3000 F +61 3 9660 4999

Australia